A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO).  (EudraCT number: 2011-000250-28)

Abstract Category

Pediatrics

Links
	Abstract 296
	Pharmacology Scientific Podium Poster Session 32
	Friday 30th August 2013
	16:55 - 17:00
	116
	Pediatrics Clinical Trial Detrusor Overactivity
	1. Astellas Pharma Europe B.V., 2. Astellas Pharma US B.V., 3. Pomnik-Centrum Zdrowia Dziecka Warsaw
Presenter
B Brigitte Bosman Astellas Pharma Europe B.V.
Abstract PDF Edit Abstract Abstract Centre